Skip to main content

Table 3 Best corrected visual acuity changes compared with baseline during follow-up

From: Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study

  

Mean ± SD

Median (range)

Baseline

LogMAR

0.66 ± 0.47

0.6 (0,1.79)

Month 3

LogMAR

0.51 ± 0.33

0.4 (0,1.39)

 

Change

−0.15 ± 0.23

−0.1 (−0.61,0.20)

 

P-value within

0.017

 

Month 6

LogMAR

0.57 ± 0.37

0.5 (0,1.48)

 

Change

−0.09 ± 0.29

0 (−0.61,0.60)

 

P-value within

0.223

 

Month 9

LogMAR

0.5 ± 0.38

0.4 (−0.12,1.48)

 

Change

−0.16 ± 0.25

−0.18 (−0.61,0.30)

 

P-value within

0.023

 

Month 12

LogMAR

0.52 ± 0.38

0.4 (−0.12,1.48)

 

Change

−0.16 ± 0.22

−0.12 (−0.61,0.40)

 

P-value within

0.016

 
  1. LogMAR logarithm of minimum angle of resolution